Development of a Qualification Plan for the PROMIS Short Form v2.1-Physical Function-Multiple Sclerosis 15a (DDT COA #000123)

Project: Research project

Project Details


We propose the preparation of a Qualification Plan to support qualification of the PROMIS® Short Form v2.1—Physical Function-Multiple Sclerosis 15a (PROMIS PFMS—15a) as a patient-reported outcome measure of physical function in individuals diagnosed with all forms of multiple sclerosis (MS). Over 1 million people in the United States are living with MS, a disease that has significant impacts on physical functioning and its associated quality of life. For example, many of the symptoms of MS (e.g., fatigue, weakness, spasticity, numbness) limit physical function, such as the ability to carry out activities of daily living (e.g., household chores and personal care) and other physical activities (e.g., rising from sitting, standing for a short time, and climbing a flight of stairs). However, a psychometrically sound, publicly available measure of physical function optimized for persons with MS has not been recognized by the FDA as fit-for-purpose for use in drug development. A measure of physical function was accepted into the Center for Drug Evaluation and Research’s (CDER’s) Clinical Outcome Assessment (COA) Qualification Program under DDT #000123 on June 21, 2017. The PRO Consortium’s MS Working Group has selected the PROMIS PFMS—15a as the physical function measure for qualification as it has been optimized for use in persons with MS. The next step in the qualification process will be to submit a Qualification Plan to the FDA to address the MS Working Group’s research plan for obtaining the quantitative evidence necessary to support qualification of the measure for use in MS drug development. Our approach includes two aims. For Aim 1, we will develop the final protocol and cross-sectional and longitudinal statistical analysis plans for an existing dataset that includes the PROMIS PFMS—15a. Planned analyses will examine the measure’s validity, reliability, and responsiveness as an outcome measure in MS populations. The protocol and analysis pla
Effective start/end date8/1/207/31/22


  • Critical Path Institute (DDT COA #000123-01 // 1 U01 FD006999-01)
  • Food and Drug Administration (DDT COA #000123-01 // 1 U01 FD006999-01)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.